Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

president of Merck Research Laboratories. "We continue to augment our oncology pipeline and look forward to working with the Kelun-Biotech team to advance these candidates to the patients that ...

Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular disease is a big opportunity as it remains an epidemic, killing 35 million people during the pandemic while ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most oversold S&P 500 stocks in 2024. Strong economic growth and the prospect of declining ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...